Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

New-wave diagnostics

A new breed of high-cost diagnostics are entering a commercial and regulatory environment that isn't designed for them. Can they prosper?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Diagnostic revenues for 2005 among the leading diagnostic companies.
Figure 2: Commercial pharmacogenomics tests by category.
Figure 3: Predicting cancer recurrence.

References

  1. Pray, L.A. Molecular Diagnostics: New Growth, New Markets (Cambridge Healthtech Advisors, Waltham, MA, 2005).

    Google Scholar 

  2. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

    Article  CAS  Google Scholar 

  3. van de Vijver, M. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. New-wave diagnostics. Nat Biotechnol 24, 931–938 (2006). https://doi.org/10.1038/nbt0806-931

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0806-931

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing